Clinical Trial Update: Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sugammadex with neostigmine for reversal of rocuronium or vecuronium at reappearance of T2 in general anesthesia; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anesthesia-related Conditions

Drugs mentioned

• Neostigmine (neostigmine)
• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Anesthesia, General | Phase 3 | Status: COMPLETED | Results posted: 2019-02-18